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ABSTRACT
Mouse double minute 2 (Mdm2) and MdmX dimerize in response to low levels 
of genotoxic stress to function in a ubiquitinating complex, which signals for 
destabilization of p53. Under growth conditions, Mdm2 functions as a neddylating 
ligase, but the importance and extent of MdmX involvement in this process are largely 
unknown. Here we show that when Mdm2 functions as a neddylating enzyme, MdmX 
is stabilized. Furthermore, we demonstrate that under growth conditions, MdmX 
enhances the neddylation activity of Mdm2 on p53 and is a substrate for neddylation 
itself. Importantly, MdmX knockdown in MCF-7 breast cancer cells resulted in 
diminished neddylated p53, suggesting that MdmX is important for Mdm2-mediated 
neddylation. Supporting this finding, the lack of MdmX in transient assays or in 
p53/MdmX-/- MEFs results in decreased or altered neddylation of p53 respectively; 
therefore, MdmX is a critical component of the Mdm2-mediated neddylating complex. 
c-Src is the upstream activator of this Mdm2-MdmX neddylating pathway and loss 
of Src signaling leads to the destabilization of MdmX that is dependent on the RING 
(Really Interesting New Gene) domain of MdmX. Treatment with a small molecule 
inhibitor of neddylation, MLN4924, results in the activation of Ataxia Telangiectasia 
Mutated (ATM). ATM phosphorylates Mdm2, converting Mdm2 to a ubiquitinating 
enzyme which leads to the destabilization of MdmX. These data show how distinct 
signaling pathways engage neddylating or ubiquitinating activities and impact the 
Mdm2-MdmX axis.
INTRODUCTION
Post-translational modifications such as ubiquitin, 
sumo, nedd8, and ISG15, are essential for a myriad of 
fundamental processes in the cell. These modifications can 
induce conformational changes to recruit binding partners, 
prevent or enhance interactions, or result in changes 
in cellular localization. E1, E2 and E3 enzymes are 
responsible for conjugating these covalent modifications 
to proteins. Mouse double minute 2 (Mdm2) is one of over 
a thousand E3 ubiquitin ligases. Mdm2 is an oncoprotein 
that is elevated in 10% of all human cancers and 40-80% 
of high-grade human tumors [1, 2]. It is most widely 
recognized for its role in facilitating ubiquitination of p53, 
which can lead to p53 destabilization under conditions of 
genotoxic stress.
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In response to low levels of DNA damage, 
Mdm2 has been described to act: as a monomer after 
phosphorylation by Ataxia Telangiectasia Mutated (ATM) 
[3, 4], as a homodimer [4–10], or as a heterodimer with 
MdmX [5-9, 11-15] after phosphorylation by c-Abl 
[16] in a ubiquitination complex. The post-translational 
modifications that dictate whether Mdm2 acts as a 
monomer, homo- or heterodimer are only beginning to 
be elucidated. While the Mdm2-MdmX heterodimer 
has been shown to have ubiquitin ligase activity [11], it 
is most commonly accepted that MdmX does not have 
ubiquitin ligase activity by itself. Most studies have 
investigated MdmX-Mdm2-p53 signaling under DNA 
damage, and agree that MdmX is destabilized under 
these conditions due to Mdm2-mediated ubiquitination of 
MdmX (reviewed by [17]). MdmX is related to Mdm2 
(C-terminal domains are 46% identical), and can bind 
directly to the transactivation domain of p53 to inhibit 
p53 transcriptional activity [18]. MdmX is also considered 
an oncogene by its ability to transform primary cells and 
is amplified in approximately 65-85% of infiltrating 
ductal breast carcinomas [19], retinoblastomas [20] and 
metastatic melanomas [21].
Interestingly, Mdm2 is one of a small number 
of E3 ligases that can mediate neddylation [22]. We 
previously demonstrated that under growth conditions, 
Mdm2 is a substrate for Src phosphorylation at Y281 
and Y302, which converts Mdm2 from a ubiquitin to a 
Nedd8 E3 ligase [23]. This Nedd8 activity of Mdm2 
results in neddylated p53 that has increased stability but 
is transcriptionally inactive.
In the current study, we show that conversion of 
Mdm2 to a neddylating enzyme by growth signaling 
results in Mdm2 forming a heterodimer with MdmX. 
This dimerization is dependent on Src phosphorylation 
of Mdm2. We also show that MdmX is conjugated with 
Nedd8. As expected, in the presence of Src, Mdm2, and 
MdmX, p53 neddylation is enhanced, thereby blocking 
p53 transcriptional activity. However, inhibition of the E1 
neddylating enzyme by MLN4924 (Pevonedistat -Takeda 
/Millennium Pharmaceuticals, Inc.) leads to the activation 
of p53. This is a multi-faceted mechanism whereby 
MdmX levels are dramatically decreased in addition 
to the prevention of neddylation. This destabilization 
is dependent on Mdm2. Our data show how multiple 
signaling pathways regulate the stability of MdmX and 
the regulation of p53.
RESULTS
Modulation of MdmX levels in response to post-
translational modifications
Mdm2 acts as a neddylating ligase in response to Src 
phosphorylation [23], but the effect on MdmX is unknown. 
When MdmX was transiently co-expressed with Mdm2 
in H1299 cells, MdmX levels decreased dramatically 
compared to MdmX expression alone (Figure 1A top 
panel). This result was expected as down-regulation of 
MdmX in response to overexpression of Mdm2 has been 
reported in the literature [24, 25]. This affect was reversed 
with the addition of constitutively active Src (CA-Src). 
To show that these observations were dependent on the 
Src phosphorylation sites on Mdm2, we used the Src 
phosphorylation double mutant Y281/302F Mdm2 in the 
presence of CA-Src and MdmX. We found that CA-Src 
failed to rescue MdmX levels in the presence of the Mdm2 
Y281/302F mutant (Figure 1A bottom panel). These data 
provide evidence that Src phosphorylation of Mdm2 
prevents Mdm2-mediated destabilization of MdmX.
We next examined if we could see similar results 
in an endogenous system through pharmacological 
approaches. Serum starved MCF7 cells were treated with 
DMSO and EGF (epidermal growth factor), or PP1 (an 
inhibitor of Src) and EGF. Mdm2 and MdmX increased in 
the presence of EGF (Figure 1B). This increase in MdmX 
levels was attenuated in the presence of PP1. While PP1 
blocks c-Src activity, Src abundance was not affected 
under these conditions (Figure 1B). These endogenous 
results show that MdmX levels are sensitive to the Src/
Mdm2 pathway.
Compared to Mdm2 and p53, there is much less 
known about protein interactions that affect MdmX levels 
and function. When Y99 of MdmX is phosphorylated by 
c-Abl, interaction with p53 is prevented [26]. In addition, 
c-Abl drives Mdm2-MdmX complex formation, which 
leads to degradation of this complex [16]. Mutation 
of P369G disrupts binding to 14-3-3
γ
, which normally 
occurs upon irradiation exposure to UV to inhibit p53 
ubiquitination [27]. We tested if a Y99F and a P369G 
mutant of MdmX were altered in response to Src signaling 
by transient expression in H1299 cells. Similar to the 
results shown in Figure 1A, the levels of MdmX, as well 
as each of the mutants, increased in the presence of CA-
Src (Figure 1C). Overall, these results show that growth 
signaling results in increased protein levels of MdmX.
Mdm2 and MdmX interact under growth 
conditions
Since MdmX levels were dependent on Mdm2, 
we wanted to determine where MdmX and Mdm2 were 
localized in the cell under growth conditions (+EGF). 
Using immunofluorescence confocal microscopy we show 
that MdmX and Mdm2 were predominantly co-localized 
in the nucleus, but also in the cytoplasm of MCF7 cells 
(Figure 2A).
We then investigated if MdmX would co-purify 
with Mdm2. Indeed, in response to active Src, Mdm2 
co-purified with MdmX when transiently expressed in 
H1299 cells (Figure 2B). In addition, every MdmX mutant 
tested was able to co-purify with Mdm2 in the presence 
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Figure 1: Conversion of Mdm2 to a neddylating ligase 
results in increased levels of MdmX as detected by 
western blot analysis. (A) Without CA-Src in the H1299 
transient transfections, Mdm2 acts as a ubiquitinating ligase 
and MdmX levels are decreased. The addition of CA-Src 
results in recovery of MdmX levels (top). The Y281-302F (Src 
phosphorylation sites) Mdm2 mutant cannot act as a neddylating 
ligase and MdmX levels cannot be rescued by CA-Src (bottom). 
(B) Endogenous levels of MdmX and Mdm2 increase with EGF 
treatment and this increase is attenuated with PP1 treatment. (C) 
Similar transfection as in A, but with various MdmX mutants 
showing that the CA-Src/Mdm2 mediated increase in MdmX 
levels is independent of these mutations. Asterisks indicate non-
specific bands. All panels: number underneath the lanes represent 
the ratio of the intensity of the MdmX band to the intensity of the 
actin band as determined by ImageJ.
of CA-Src (Figure 2B). We observed that the amount of 
Mdm2 immunoprecipitated in the presence of Src was 
increased in our experiments. To ensure that the increase 
in interaction between MdmX and Mdm2 was due to post-
translational modifications and not due solely to increased 
expression levels, we used a cell free approach with 
bacterially produced recombinant proteins and found that 
the interaction between GST- Mdm2 and His-MdmX was 
increased in the presence of active Src (Figure 2C). This 
finding suggests that binding of Mdm2 with MdmX is not 
an artifact of increased protein levels and the increase in 
association was in response to phosphorylation.
To validate these findings, the endogenous 
interaction between MdmX and Mdm2 under growth 
conditions was investigated. MdmX co-purified with 
Mdm2 that was immunoprecipitated from EGF treated 
MCF7 cells (Figure 2D). Taken together, these results 
demonstrate that under growth conditions, when Mdm2 
is phosphorylated by Src and acting as a neddylating 
enzyme, Mdm2 interacts with and increases MdmX.
The complex formation and increased MdmX 
abundance could be a result of neddylation by Mdm2. 
To test this, we transiently transfected H1299 cells with 
combinations of His-Nedd8, Myc-MdmX, HA-Mdm2 
and CA-Src and performed a nickel pull-down assay. We 
found that MdmX was neddylated only in the presence 
of both Mdm2 and CA-Src (Figure 2E). This result also 
shows that in the presence of active Src, MdmX was 
unable to be neddylated in the absence of Mdm2 (Figure 
2E). Reprobing the membrane showed that neddylation 
of Mdm2 also depends on Src (Supplementary Figure 
1). Taken together, our data demonstrates that Mdm2 
and MdmX form a neddylating complex that leads to 
neddylation of MdmX.
MdmX enhances neddylation of p53
Considering that Mdm2 and MdmX form an 
active neddylating complex, we next examined if this 
complex was able to neddylate p53. A nickel pull-down 
assay showed that neddylation of p53 was more robust 
in the presence CA-Src and MdmX (Figure 3A and 3B). 
In the absence of exogenous MdmX, p53 neddylation 
was noticeably decreased. As predicted, transfection of 
kinase dead Src (KD-Src) resulted in less p53 neddylation 
compared to no Src overexpression (Figure 3A and 3B). 
To provide additional support for the requirement of 
an Mdm2-MdmX neddylation complex, we repeated 
the nickel pull-down assay and included MLN4924. 
Treatment with MLN4924 diminished neddylation of p53 
despite expression of Mdm2, MdmX, and CA-Src (Figure 
3B). Next, we transiently transfected mutant p53 D281G 
(to prevent lethality caused by p53 expression), CA-Src, 
and His-Nedd8 into p53-/-, p53 -/- MdmX -/-, p53-/- 
Mdm2-/-, and p53-/- MdmX-/- Mdm2 -/- MEFs. A nickel 
pull-down was then conducted, and while the presence 
of Mdm2 alone was sufficient for the faster migrating 
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forms of neddylated p53, MdmX was necessary for the 
slower migrating forms of neddylated p53 (Figure 3C) in 
a murine system.
To further our analysis, we immunoprecipitated 
endogenous Nedd8 from shControl and shMdmX MCF7 
cells and blotted for p53. We found that neddylated p53 
was observed in shControl cells, but not in the shMdmX 
cells (Figure 3D; total p53 levels shown in Supplementary 
Figure 2). This endogenous data provides insight into 
signaling and neddylation of p53 under physiological 
conditions. Collectively, our data supports a key role for 
MdmX in enhancing Mdm2-mediated neddylation of p53.
MLN4924 treatment results in decreased levels 
of MdmX
Since MdmX is neddylated (Figure 2E) and is 
involved in neddylating p53 (Figure 3), we wanted to 
investigate the effect of inhibiting neddylation with 
MLN4924, a small molecule inhibitor of Nedd8-
activating enzyme. As expected, incubation of MCF7 and 
U87 cells with 0.3 μm MLN4924 resulted in decreased 
protein levels of MdmX (Figure 4A). Furthermore, this 
decrease was abrogated with treatment of 20 μM MG132, 
which suggests that MLN4924 results in proteosomal 
degradation of MdmX.
Since Mdm2 can ubiquitinate MdmX and target it 
for degradation through the proteosome, we examined 
whether Mdm2 was necessary for this MLN4924-mediated 
decrease of MdmX. Considering that genetically removing 
Mdm2 from cells that are wild type for p53 is lethal, we 
knocked out Mdm2 using CRISPR/Cas9 targeted to Exon 
12 of Mdm2 in TMD231 cells [a derivative of MDA231 
(mutant p53 R280K)]. After confirmation of Mdm2 
knockout (Figure 4B left panel), cells were treated with 
MLN4924. As expected, a decrease in MdmX levels was 
detected in the vector control cells, which was not evident 
in the Mdm2 knock-out cells (Figure 4B right panel). 
This result verifies that MdmX degradation in response to 
MLN4924 is dependent on Mdm2.
To further explore this mechanism of Mdm2-
mediated MdmX destabilization in response to 
MLN4924, we generated several MCF7 and U87 cell 
lines by viral transduction: vector control, wildtype 
MdmX, or MdmX with a C-terminal truncation that lacks 
a RING domain (ΔC MdmX) and is unable to interact 
with Mdm2 [14]. Figure 4C shows that, similar to Figure 
4A, MLN4924 treatment decreased wildtype MdmX 
levels. However, this drug had no effect on ΔC MdmX, 
suggesting that binding with Mdm2 (via the RING 
domain) is necessary for MLN4924 mediated decrease 
of MdmX.
The Mdm2-mediated decrease of MdmX could be 
due solely to the inhibition of neddylation by MLN4924. 
Alternatively, we postulated that MLN4924 could be 
converting Mdm2 to be a ubiquitinating enzyme as 
Figure 2: MdmX and Mdm2 interact under growth conditions. (A) Confocal microscopy shows that MdmX and Mdm2 (red 
and green respectively in the top row or green and red respectively in the bottom row) are co-localized in the nucleus. (B-D) MdmX is in 
a complex with Mdm2 as determined from western blot analysis of immunoprecipitated extracts from transiently transfected H1299 cells 
(B), recombinant GST-Pulldowns (C), and immunoprecipitated MCF7 whole cell lysates (lanes spliced from the same gel after formatting) 
(D). (E) Western blot of a nickel pull-down of His-tagged Nedd8 showing that MdmX is neddylated in a CA-Src and Mdm2 dependent 
fashion. Asterisks indicate non-specific bands.
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MLN4924 was previously reported to activate ATM [28]. 
ATM has been shown to phosphorylate Mdm2 [3, 4, 29, 
30] and MdmX [31] resulting in MdmX degradation after 
genotoxic stress. To determine if ATM was involved in 
MLN4924-mediated degradation of MdmX, we treated 
MCF7 cells with a combination of MLN4924 and 
caffeine (an ATM inhibitor). Inhibiting ATM rescued 
the MLN4924-mediated decreased in wildtype MdmX 
levels (Figure 4C). This result was validated with a more 
specific ATM inhibitor (KU-55933) (Supplementary 
Figure 3). Taken together, these results suggest that 
MLN4924 activates ATM, which then results in Mdm2-
mediated degradation of MdmX through the ring domain 
of MdmX.
p53 is phosphorylated, stabilized and activated 
by the MLN4924-ATM-Mdm2-MdmX pathway
As p53 is a substrate for ATM, we wanted to 
confirm that ATM was activated by MLN4924. Upon 
MLN4924 treatment, pS15 of p53 (an established ATM 
phosphorylation site) was detected, thus indicating 
ATM activation (Figure 5A). This phosphorylation was 
attenuated with the addition of caffeine, supporting that 
ATM was the responsible kinase. In addition, the amount 
of total p53 increased with MLN4924 treatment and this 
result was mitigated with the combination of MLN4924 
and caffeine (Figure 5A).
Previously, we have shown that increased p53 levels 
do not necessarily result in increased activity. To assess 
Figure 3: Wildtype and mutant p53 is neddylated in a MdmX-dependent manner as determined by western blot 
analysis. (A) Nickel pull-down of His-Nedd8 showing that neddylation of p53 is dependent on MdmX and CA-Src. (B) Same Nickel 
pull-down as in A, but with the addition of MLN4924. MLN4924 decreases neddylation of p53. (C) Transient transfection of MEFs with 
CA-Src. His-Nedd8 and either Myc-LacZ or Mutp53. The presence of MdmX changes the banding pattern of neddylated p53. (D) MdmX 
was silenced in shMdmX MCF7 cells (left panel). Neddylated p53 was immunoprecipitated in the presence of MdmX, but not when MdmX 
was knocked down (right panel) (H.C.= Heavy Chain). All Panels: Asterisks indicate non-specific bands.
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Figure 4: Westerns showing that MLN4924 decreases MdmX levels and this decrease depends on the proteasome, 
Mdm2, the C-terminus of MdmX and ATM activation. (A) MLN4924 treatment decreases MdmX levels in both MCF7 (left 
panel) and U87 (right panel). Concurrent treatment with 20 μM MG132 (Velcade) rescues MdmX levels. (B) CRISPRed TMD231 cells 
that lack full length Mdm2 (left panel) do not have decreased MdmX in response to MLN4924 (right panel). (C) Co-treatment with 2 mM 
caffeine (ATM inhibitor) prevents the MLN4924-mediated decrease in MdmX levels. Therefore, intact signaling through the ATM pathway 
is required. Also, MdmX lacking the C-terminus is unresponsive to MLN4924. Panels A and C: number underneath the lanes represent the 
ratio of the intensity of the MdmX band to the intensity of the actin band as determined by ImageJ.
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p53 activity, we investigated the effect of MLN4924 
treatment on p21 and found that p21 was also increased 
with MLN4924 treatment (Figure 5B). This result suggests 
that p53 is transcriptionally active upon MLN4924 
treatment.
Lastly, we conducted fluorescence-activated cell 
sorting to determine if there were any aberrations in the 
cell cycle. Treatment of actively growing MCF7 cells 
with MLN4924 for 18 h resulted in a higher proportion 
of cells in the G1 phase and less cells in the G2 phase of 
Figure 5: MLN4924 results in p53 activation and cell cycle arrest. (A) Western blots of MCF7 (left) and U87 (right) extracts 
showing that S15 of p53 is phosphorylated in response to MLN4924 treatment but not with the addition of caffeine. (B) Western analysis 
of extracts from MCF7 (left) and U87 (right) cells showing increased levels of p21 in response to MLN4924. (C) Flow cytometry of MCF7 
cells showed MLN4924-treated cells were arrested in G1.
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the cell cycle (Figure 5C). Disruption of cell cycle upon 
MLN4924 is consistent with previous reports in Urothelial 
carcinoma [32], Ewing Sarcoma [33], Gastric cancer [28], 
melanoma [34] and breast cancer [35].
DISCUSSION
It is well established that Mdm2 and MdmX can 
form heterodimers via their RING finger domains [9, 13–
15]. However, how the complex is formed and the possible 
function(s) of this heterodimer under growth signaling has 
not been explored. We show that under growth conditions, 
MdmX is increased, the MdmX-Mdm2 heterodimer 
does form, and MdmX is neddylated. This is the first 
evidence that growth conditions regulate an increase of an 
oncoprotein complex.
Furthermore, since MdmX levels of all mutants were 
increased under conditions of growth, signaling through 
those pathways dependent on the wild-type residues are 
unlikely to be involved. Although the C464S mutant 
was tested (Figure 2B), it has been shown that MdmX 
overexpression can compensate for ring domain mutants 
of Mdm2 [9] and one can surmise that the reverse is also 
true. Since Mdm2 is stabilized when Src is active [23], it 
is possible that it is able to rescue the C464S mutant of 
MdmX.
There has been considerable interest in the 
development of therapeutics that modulate the regulation 
of kinase pathways and limited development on those 
that impact other post-translational modifications. One 
such small molecule, MLN4924, is a specific inhibitor of 
the NEDD8-activating enzyme in Phase 2 clinical trials. 
However, its effect on the regulation of p53 has not been 
fully explored. There have been reports that MLN4924 can 
elicit DNA stress type responses [35–38] in addition to 
preventing neddylation.
The majority of studies on the Mdm2-MdmX 
interaction have been conducted under conditions of 
Figure 6: Illustration of how MdmX is integrated into growth factor-mediated neddylation. Under growth conditions, 
Mdm2 and MdmX form a complex that is necessary to neddylate MdmX and p53. This function is inhibited by MLN4924 which also 
activates ATM. ATM activation results in conversion of Mdm2 to a ubiquitinating complex, which leads to MdmX destabilization, but not 
p53 degradation.
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DNA damage. We have shown that c-Abl phosphorylation 
of Mdm2 results in Mdm2-MdmX complex formation 
and ubiquitination of MdmX [16]. Other studies have 
shown that ATM activation after DNA damage results in 
ATM-mediated phosphorylation of Mdm2, which blocks 
nuclear export of p53 [30] and MdmX, which results 
in rapid destabilization of MdmX. In addition, ATM 
phosphorylation prevents poly-ubiquitination of p53 by 
inhibiting homodimerization of Mdm2 [4]. DNA damage 
has also been reported to result in checkpoint kinase 
(Chk) [27, 31, 39, 40] and ribosomal stress pathway 
[3, 41–44] activation, similarly resulting in MdmX 
degradation.
Another component that could be contributing to 
MdmX degradation under DNA damaging conditions is 
the activation of NEDP1. This isopeptidase is induced 
by chemotherapy and can de-neddylate Mdm2 [45]. It is 
conceivable that the DNA damage response that is initiated 
by MLN4924 treatment is activating NEDP1, which then 
de-neddylates Mdm2 and/or MdmX resulting in loss 
of MdmX. Our study illustrates that MdmX stability is 
sensitive to MLN4924.
The seminal finding of this study is the contribution 
of MdmX to the neddylation of p53. Initial work suggested 
the involvement of MdmX as part of a neddylating 
complex and reported that while co-expression of MdmX 
did not significantly affect Mdm2-mediated neddylation 
of p53, it was sufficient to rescue Mdm2 mutants that had 
impaired neddylation activity in transient transfections [9]. 
However, the mechanism by, and conditions under, which 
Mdm2 switches from ubiquitinating to neddylating activity 
was not yet known. In the current study, we show by 
transient overexpression in H1299 cells that the maximum 
amount of neddylated p53 is absolutely dependent on 
MdmX. Furthermore, if CA-Src is replaced with KD-Src 
or the cells are treated with MLN4924, this neddylation 
is diminished. In MEFs, the neddylation pattern is 
significantly different when MdmX is present compared 
to when it is absent. Importantly, MdmX contributes to 
neddylation endogenously as immunoprecipitation of 
Nedd8 from shMdmX MCF7 cells, followed by western 
blotting shows much less or almost no neddylated p53 
compared to the control. Thus, corroborated by multiple 
experimental models and approaches, we show that 
MdmX greatly enhances the neddylation capacity of 
Mdm2.
Taken together, our results show that during growth 
conditions when Src is active, Mdm2 and MdmX are in a 
complex together to neddylate p53 and MdmX. Inhibition 
of this activity with MLN4924 results in ATM activation, 
MdmX degradation, and increased p21 (Figure 6). This 
study highlights the complexity of signaling pathways 
that affect Mdm2-MdmX enzymatic activity within the 
cell and emphasizes the need to carefully consider this 
intricacy in future studies or when targeting this pathway 
for therapeutic intervention.
MATERIALS AND METHODS
Cell culture and treatments
The shMdmX, MdmX, and ΔC MdmX constructs 
were obtained [46]. Lentiviral CRISPR to Mdm2 was 
created with forward and reverse Mdm2 CRISPR 
primers (CACCGTTGGGCCCTTCGTGAGAAT and 
AAACATTCTCACGAAGGGCCCAAC respectively) 
to exon 12 cloned into the Lenticrispr vector (pXPR_001 
obtained from Clark Wells) as described [47].
Viral transductions were conducted as described 
[48]. H1299, U87, TMD231, MEF and MCF7 cells were 
incubated at 37°C in a humidified chamber with 5% CO2 
in DMEM high glucose and 8-10% fetal bovine serum. 
Transient transfections were performed using 1:1 DNA 
to PEI (H1299). Equal amounts of DNA were transfected 
into cells except for neddylation assays (see figure 
legend). Unless indicated, cells were treated with 0.3 μm 
MLN4924 (Life Sensors), 2 mM Caffeine and/or 10 μM 
ATMi (KU-55933 (Millipore) for 18 h.
Protein analysis
Cell pellets were lysed in Urea Lysis Buffer 
(20mM Tris pH6.8, 100 mM NaH2PO4, 6M Urea) on ice 
for 2 hours and sonicated before centrifugation. After 
quantitation, proteins were analyzed by western blotting. 
All antibodies are listed in Supplementary Table 1.
Immunoprecipitation
Cells were lysed in 25 mM Tris-HCl, 150 mM NaCl, 
1% IGEPAL, protease cocktail, 1 mM Na3VO4, 10 mM 
NaF, 1 μm Sodium Pyrophosphate (pH 8.0) and sonicated. 
Antibodies were preabsorbed, washed and then incubated 
with lysate at 4°C for 2 h. All antibodies are listed in 
Supplementary Table 1.
Kinase and other in vitro reactions
Kinase reactions were performed at 30°C for 60 
minutes in kinase buffer (60 mM HEPES, pH 7.4, 3 mM 
MgCl2, 3 mM MnCl2, 3 μm Na3VO4, 20 mM ATP) using 
0.1 μg of Src (Millipore). Kinase reactions were incubated 
with glutathione-sepharose beads that were pre-washed in 
0.1% DTT for 30 minutes. This incubation was conducted 
for 10 minutes in a 0.1% DTT buffer. Complexes that 
formed were spun down and washed four times in a high 
salt buffer (0.5 M KCl, 20 mM Tris, 0.1% IGEPAL, pH 
8.0). The bound proteins were eluted in SDS-Loading 
Buffer and western blot analysis was performed.
Nickel pull down
H1299 cells were transfected with His-nedd8 and 
other plasmids using PEI (1 DNA:1 PEI ratio). Twenty-
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four hours after transfection, cells were lysed in 500 μl 
of 6 M guanidinium–HCl, 0.1 M Na2HPO4/NaH2PO4, 
0.01 M Tris–HCl pH 8.0 plus 5 mM imidazole and 10 
mM ß-mercaptoethanol. After centrifugation, the lysates 
were mixed with 30 μl of Ni2+-NTA-agarose beads 
(Qiagen) prewashed with lysis buffer and incubated for 
2 h at room temperature. The beads were successively 
washed in each of the following: 6 M guanidinium–
HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris–HCl pH 
8.0 plus 10 mM ß-mercaptoethanol; 8 M urea, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris–HCl pH 8.0, 10 mM 
ß-mercaptoethanol; 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 
0.01 M Tris–HCl pH 6.3, 10 mM ß-mercaptoethanol plus 
0.2% Triton X-100; 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 
0.01 M Tris–HCl pH 6.3, 10 mM ß-mercaptoethanol plus 
0.1% Triton X-100. After the last wash the beads were 
eluted with 200 mM imidazole in 5% SDS, 0.15 M Tris–
HCl pH 6.7, 30% glycerol, 0.72 M ß-mercaptoethanol. 
Eluates were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS–PAGE) and 
western blotting.
Confocal analysis
MCF7 cells growing on coverslips were serum 
starved for 72 hours and then treated for EGF for 8 hours. 
Cells were washed in PBS and then fixed for one hour 
at room temperature in 4% paraformaldehyde. After 
3 washes in PBS, cells were permeabilized in 0.1% 
Triton-X 100 for 20 minutes. and washed 3X in PBS. 
After blocking in 2% BSA, coverslips were incubated 
with MdmX and/or Mdm2 antibodies (Red Mdm2 – N20, 
Green Mdm2 – SMP14, Red MdmX – Bethyl, Green 
MdmX – 8C6) overnight at 4° C and washed 3X in PBS. 
Coverslips were then incubated with AlexaFluor 488 
and 637 linked to anti-mouse and anti-rabbit secondary 
antibodies (respectively) for 1 hour, washed 3X in PBS, 
mounted on slides with Prolong Diamond Antifade 
Mountant with DAPI and visualized with a Leica SP8 MP 
confocal microscope at room temperature. Images were 
obtained using HC PL APO 40x/1.3 oil CS2 objective 
and the Leica Application Suite Advanced Fluorescence 
Software provided by the Indiana Center for Biological 
Microscopy core.
Cell cycle analysis
MCF-7 cells (3×105) were plated onto 6-well 
plates in triplicates and serum starved for 24 h. Cells 
were released from starvation with DMEM complete and 
treated with DMSO or MLN (0.6 μM) for 18 h, cells were 
washed with 1X PBS, harvested with trypsin, and spun at 
300g x 5 minutes. FACS analysis was performed on the 
Muse (Millipore) with the Muse Cell Cycle Kit, according 
to manufacturers instructions (5,000 events). Significance 
was calculated using Two-tailed Student’s T-Test.
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